Poland Bioinformatics Market Report 2022 to 2030

Poland Bioinformatics Market Analysis

$ 3999

The Poland Bioinformatics market is projected to grow from $89.03 Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The main factors driving the growth would be an as increasing prevalence of chronic disease, advances in technology, and the growing pharmaceutical industry. The market is segmented by technology and by application. Some of the major players include Ardigen (POL), genXone (POL), Ideas4biology (POL), Agilent Technologies, IBM Life Sciences, and Qiagen.

ID: IN10PLHS001 CATEGORY: Healthcare Services GEOGRAPHY: Poland AUTHOR: Neha Davda

Buy Now

Poland Bioinformatics Market Executive Summary

The Poland Bioinformatics market is projected to grow from $89.03 Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. In 2019, national healthcare spending in Poland as a percentage of GDP reached 6.45% achieving $1,014 per capita. Poland has consistently spent less on health during the previous 10 years than the average EU country, both in terms of per-capita spending and as a percentage of GDP.

Bioinformatics is a growing area of biological study created by fusing biology and information technology. Using biological technologies, this industry primarily focuses on the analysis of biological data and the creation of new software. The study of genomics, proteomics, 3D protein structure modeling, image analysis, drug creation, and many more fields make extensive use of bioinformatics. The European region holds the second-largest market share for bioinformatics globally.

poland bioinformatics market analysis

Market Dynamics

Market Growth Drivers

The Poland bioinformatics market is expected to be driven by factors such as the increasing prevalence of chronic disease, advances in technology, and the growing pharmaceutical industry. The development of the bioinformatics sector is also being fuelled by Poland's booming pharmaceutical industry, as businesses look to use bioinformatics tools to support drug discovery and development.

Market Restraints

The factors that are limiting the growth of the bioinformatics market in Poland are the lack of skilled professionals and insufficient funding from the government for research and development. Poland's low governmental R&D spending, which was less than 1% of GDP in 2020, will restrict the growth of the country's bioinformatics sector.

Competitive Landscape

Key Players

Ardigen (POL)
genXone (POL)
Ideas4biology (POL)
Agilent Technologies
IBM Life Sciences
Qiagen

Healthcare Policies and Regulatory Landscape

The Ministry of Health is the regulatory and policy-making authority in charge of establishing regulations governing the operation of the healthcare system, and large capital expenditures in healthcare, medical science, and education. The National Health Fund (NFZ), which is in charge of overseeing and funding the public healthcare system in Poland, is based on the principle of universal access to healthcare services. But the government's emphasis on cost-cutting measures might make it challenging for businesses to invest in pricey bioinformatics technologies.

Companies operating in Poland's bioinformatics sector must adhere to all applicable EU medical device rules, such as the Medical Devices Regulation (MDR) and the In-Vitro Diagnostics Regulation (IVDR). These laws cover post-market vigilance and surveillance, as well as standards for product performance and safety. Additionally, bioinformatics companies must also abide by Polish laws and regulations related to data protection and security, such as the General Data Protection Regulation (GDPR) and the Act on Personal Data Protection.

Reimbursement Scenario

Poland's public healthcare system is managed and financed by the National Health Fund (NFZ), which also establishes regulations for paying for medical products and services. In Poland, reimbursement for medical goods and services is typically based on a "positive list" system, which means that only goods and services that are on the list are eligible for reimbursement. When requesting reimbursement, applicants must submit a dossier from the Agency for Health Technology Assessment and Tariff System, which contains analyses of clinical effectiveness, economics, and budgetary effects.

1. Executive Summary
1.1 Service Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Healthcare Services Market in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Services
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Bioinformatics Market Segmentation

By Technology (Revenue, USD Billion):

Knowledge Management Tools
Bioinformatics Platforms
Bioinformatics Services

By Application (Revenue, USD Billion):

Metabolomics
Molecular phylogenetics
Transcriptomics
Chemoinformatic & drug design
Genomics
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.